Healthcare Resource Utilization (HCRU) in Patients (pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated in the Connect® MDS/AML Disease Registry

被引：0
|
作者：
Mukherjee, Sudipto [1 ]
Abedi, Mehrdad [2 ]
Erba, Harry P. [3 ]
Pollyea, Daniel A. [4 ]
Roboz, Gail J. [5 ]
Thompson, Michael A. [6 ]
Louis, Chrystal U. [7 ]
Flick, E. Dawn [8 ]
Nifenecker, Melissa [7 ]
Kiselev, Pavel [7 ]
Swern, Arlene S. [7 ]
Cogle, Christopher R. [9 ]
机构：
[1] Cleveland Clin, Cleveland, OH 44106 USA
[2] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA 95817 USA
[3] Univ Alabama Birmingham, Birmingham, AL USA
[4] Univ Colorado, Denver, CO 80202 USA
[5] Weill Cornell Med Coll, New York, NY USA
[6] Advocate Aurora Hlth, Aurora Res Inst, Milwaukee, WI USA
[7] Celgene Corp, Summit, NJ USA
[8] Celgene Corp, San Francisco, CA USA
[9] Univ Florida, Gainesville, FL USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-112935
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4736
引用
收藏
页数：6
相关论文
共 50 条
  • [21] Factors Associated with Early Therapy Initiation in Patients (pts) with Myelodysplastic Syndromes (MDS) in the Connect® MDS/AML Disease Registry
    Cogle, Christopher R.
    Garcia-Manero, Guillermo
    Grinblatt, David L.
    Komrokji, Rami S.
    Savona, Michael R.
    Scott, Bart L.
    Sekeres, Mikkael A.
    Louis, Chrystal U.
    Flick, E. Dawn
    Nifenecker, Melissa
    Kiselev, Pavel
    Swern, Arlene S.
    Steensma, David P.
    BLOOD, 2018, 132
  • [22] Healthcare Resource Utilization and Costs in US Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Intensive Induction Chemotherapy
    Huggar, David
    Knoth, Russell L.
    Copher, Ronda
    Cao, Zhun
    Lipkin, Craig
    McBride, Ali
    LeBlanc, Thomas W.
    BLOOD, 2021, 138
  • [23] Assessing eligibility for non-intensive chemotherapy (IC) randomized clinical trials (RCT) in patients (pts) with newly diagnosed (ND) AML from the Connect Myeloid Disease Registry.
    Erba, Harry Paul
    Pollyea, Daniel Aaron
    Sekeres, Mikkael A.
    Garcia-Manero, Guillermo
    Seiter, Karen
    DeGutis, Irene
    Kiselev, Pavel
    McBride, Ali
    Yu, Edward
    Roboz, Gail J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] Comparative Analysis of Clinical Outcomes and Healthcare Resource Utilization (HRU) in Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Unfit for High-Intensity Chemotherapy Treated with Venetoclax ( VEN) Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative
    Desai, Pinkal
    Garcia, Jacqueline S.
    Zeidner, Joshua F.
    Abedin, Sameem
    Wolach, Ofir
    Vachhani, Pankit
    Moshe, Yakir
    Pollyea, Daniel A.
    Lai, Catherine
    LeBlanc, Thomas W.
    Xavier, Marin
    Nachmias, Boaz
    Chen, Evan C.
    Bathini, Srilakshmi
    Bhatti, Inderpreet
    Bui, Cat N.
    Guerin, Annie
    Burne, Rebecca
    Ma, Esprit
    Grunspan, Moshe
    Frankel, Neta
    Goldberg, Aaron D.
    BLOOD, 2023, 142
  • [25] Receipt of Initial Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia (AML)
    Bhatt, Vijaya
    Shostrom, Valerie
    Gundabolu, Krishna
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S280 - S281
  • [26] Treatment Patterns and Outcomes of Patients with NPM1+Acute Myeloid Leukemia (AML) Enrolled in the CONNECT® Myeloid Disease Registry
    Pollyea, Daniel A.
    Maciejewski, Jaroslaw P.
    Roboz, Gail J.
    Seiter, Karen
    Scott, Bart L.
    DeGutis, Irene S.
    Kiselev, Pavel
    Yu, Edward
    McBride, Ali
    Heydendael, Willem
    Erba, Harry P.
    BLOOD, 2022, 140 : 11844 - 11846
  • [27] Healthcare Resource Utilization and Costs Among Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients: A Retrospective Cohort Study Using Contemporary US Claims
    Huntington, Scott F.
    Chang, Hsien-Yen
    Fu, Alex Z.
    Loefgren, Christina
    Lu, Xiaoxiao
    BLOOD, 2023, 142
  • [28] Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
    Naval, Daver
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Pemmaraju, Naveen
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Jain, Nitin
    Borthakur, Gautam
    Jabbour, Elias
    Konopleva, Marina
    Cortes, Jorge E.
    Craig, Adam
    Ravandi, Farhad
    BLOOD, 2014, 124 (21)
  • [29] The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML
    Kayser, Sabine
    Doehner, Konstanze
    Krauter, Juergen
    Koehne, Claus-Henning
    Horst, Heinz A.
    Held, Gerhard
    von Lilienfeld-Toal, Marie
    Wilhelm, Sibylla
    Kuendgen, Andrea
    Goetze, Katharina
    Rummel, Mathias
    Nachbaur, David
    Schlegelberger, Brigitte
    Goehring, Gudrun
    Spaeth, Daniela
    Morlok, Carina
    Zucknick, Manuela
    Ganser, Arnold
    Doehner, Hartmut
    Schlenk, Richard F.
    BLOOD, 2011, 117 (07) : 2137 - 2145
  • [30] Tipifarnib in combination with idarubicin and cytarabine in patients with newly diagnosed acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS).
    Ravandi-Kashani, F.
    Kantarjian, H.
    Garcia-Manero, G.
    O'Brien, S.
    Verstovsek, S.
    Estrov, Z.
    Faderl, S.
    Giles, F.
    Wright, J.
    Cortes, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 351S - 351S
12345